PT - JOURNAL ARTICLE AU - Chen, Runzhe AU - Li, Jun AU - Fujimoto, Junya AU - Hu, Xin AU - Quek, Kelly AU - Tang, Ming AU - Mitra, Akash AU - Behrens, Carmen AU - Chow, Chi-Wan AU - Jiang, Peixin AU - Little, Latasha D. AU - Gumbs, Curtis AU - Song, Xingzhi AU - Zhang, Jianhua AU - Tan, Dongfeng AU - Heymach, John V. AU - Wistuba, Ignacio AU - Futreal, P. Andrew AU - Gibbons, Don L. AU - Byers, Lauren A. AU - Zhang, Jianjun AU - Reuben, Alexandre TI - Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma AID - 10.1101/2021.08.01.21260883 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.01.21260883 4099 - http://medrxiv.org/content/early/2021/08/04/2021.08.01.21260883.short 4100 - http://medrxiv.org/content/early/2021/08/04/2021.08.01.21260883.full AB - Background Lung cancer is the leading cause of cancer death, partially owing to its extensive heterogeneity. The analysis of intertumor heterogeneity has been limited by an inability to concurrently obtain tissue from synchronous metastases unaltered by multiple prior lines of therapy.Methods In order to study the relationship between genomic, epigenomic and T cell repertoire heterogeneity in a rare autopsy case from a young female never-smoker with late-stage lung adenocarcinoma (LUAD), we did whole-exome sequencing (WES), DNA methylation and T-cell receptor (TCR) sequencing to characterize the immunogenomic landscape of one primary and 19 synchronous metastatic tumors.Results We observed heterogeneous mutation, methylation, and T cell patterns across distinct metastases including a set of prevalent T cell clonotypes which were completely excluded from left-side thoracic tumors. Though a limited number of predicted neoantigens were shared, these were associated with homology of the T cell repertoire across metastases. Lastly, ratio of methylated neoantigen coding mutations was negatively associated with T-cell density, richness and clonality, suggesting neoantigen methylation may partially drive immunosuppression.Conclusions Our study demonstrates heterogeneous genomic and T cell profiles across synchronous metastases and how restriction of unique T cell clonotypes within an individual may differentially shape the genomic and epigenomic landscapes of synchronous lung metastases.Competing Interest StatementL.A.B. serves on advisory committees for AstraZeneca, AbbVie, GenMab, BergenBio, Pharma Mar SA, Sierra Oncology, Merck, Bristol Myers Squibb, Genentech, and Pfizer and has research support from AbbVie, AstraZeneca, GenMab, Sierra Oncology and Tolero Pharmaceuticals. I.W. reports grants and personal fees from Genentech/Roche, Bayer, Bristol-Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Merck, and Guardant Health; personal fees from GlaxoSmithKline and MSD; grants from Oncoplex, DepArray, Adaptive, Adaptimmune, EMD Serono, Takeda, Amgen, Karus, Johnson & Johnson, Iovance, 4D, Novartis, Oncocyte and Akoya. J.J.Z. reports research funding from Merck, Johnson and Johnson, and consultant fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed and Innovent outside the submitted work. J.V.H. reports honorariums from AstraZeneca, Boehringer-Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Guardant Health, Foundation medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Spectrum, EMD Serono, Sanofi, Takeda, Mirati Therapeutics, BMS, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, EMD Serono, Pneuma Respiratory, Kairos Venture Investments, Roche and Leads Biolabs. A.R. serves on the Scientific Advisory Board and has received honoraria from Adaptive Biotechnologies. The other authors declare no competing interests.Funding StatementThis work was supported by Conquer Cancer Foundation ASCO Young Investigator Award, MD Anderson Physician Scientist Award, Cancer Prevention & Research Institute of Texas (CPRIT) Multiple Investigator Award, TJ Martell Foundation, NIH/NCI R01-CA207295, NIH/NCI U01-CA213273 and Department of Defense (LC170171). A.R. is supported by the Exon 20 Group, Rexanna's Foundation for Fighting Lung Cancer, the Waun Ki Hong Lung Cancer Research Fund, MD Anderson's Lung Cancer Moon Shot and the University Cancer Foundation via the Institutional Research Grant program at the University of Texas MD Anderson Cancer Center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Collection and use of patient samples were approved by the Institutional Review Board of the University of Texas MD Anderson Cancer Center.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the authors upon reasonable requestCTcomputed tomographyH&Ehematoxylin and eosinJIJaccard indexLUADlung adenocarcinomaMRImagnetic resonance imagingSNVssingle nucleotide variantsSWANsubset-quantile within-array normalizationTCRT cell receptorWESwhole-exome sequencingVAFvariant allele frequency